The University of Birmingham

Founded in 1900, the University is one of the leading research-based universities in the United Kingdom; the breadth of research expertise is a distinctive characteristic of the University.

The last UK Research Excellence Framework in 2014 confirmed that 87% of the University’s research has global reach, meaning it is recognised internationally in terms of its originality, significance and rigour.

Birmingham is 82nd in the 2016 QS World University Rankings, cementing our position in the top 100 universities globally and placing us 11th out of the 24 Russell Group universities to feature in the ranking. The University of Birmingham has extensive experience of EU collaboration and partnerships.

Role in the project

The University of Birmingham will undertake the following areas of research for the project:

(1) Assessment of anxiety and depression, health-related quality of life (HRQoL) and cognitive impairment over time in patients with atrial fibrillation (AF) who survive an intracranial haemorrhage (ICH).

(2) To explore, in an embedded qualitative sub-study, patient and physician’s attitudes to antithrombotic treatment (DOAC, antiplatelet therapy or no therapy) among AF patients who are ICH-survivors.

View All Partners

The University of Birmingham

Contact Person

Professor Gregory Y H Lip, Consultant Cardiologist

Contact Email

g.y.h.lip@bham.ac.uk

Contact Person

Dr Deirdre Lane, Senior Lecturer in Cardiovascular Health

Contact Email

d.a.lane@bham.ac.uk

Link to website

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 754517